Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1/2, Open-Label, Nonrandomized, Multi-arm Umbrella Study of Biomarker-Selected Dual-Target CAR-T Cell Modules in Adults With Relapsed or Refractory Hematologic Malignancies

NCT07523555 is registered in ClinicalTrials.gov with Beijing Biotech as lead sponsor.

NCT NCT07523555
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07523555 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1/2, Open-Label, Nonrandomized, Multi-arm Umbrella Study of Biomarker-Selected Dual-Target CAR-T Cell Modules in Adults With Relapsed or Refractory Hematologic Malignancies
Lead sponsor
Beijing Biotech
Phase
Phase 1/2
Overall status
Recruiting
Start date
March 2, 2026
Completion date
February 17, 2028
Enrollment
96 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

bpdcn; relapsed/refractory t-cell acute lymphoblastic leukemia, peripheral t-cell lymphoma, relapsed/refractory acute myeloid leukemia, high-risk myelodysplastic neoplasm, relapsed/refractory b-cell acute lymphoblastic leukemia, relapsed/refractory b-cell non-hodgkin lymphoma or cll/sll, relapsed/refractory multiple myeloma or plasma cell leukemia, t-lymphoblastic lymphoma